Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids

What happened: ResearchAndMarkets.com added a report on the next-generation AAV gene therapy delivery market, covering engineered capsids, targeting, safety and scalable manufacturing. Key numbers: Market projected at $4.96 billion in 2025, $5.93 billion in 2026 (19.5% CAGR), and $11.91 billion by 2030 (19.1% CAGR from 2026). Why it matters: The report points to engineered capsid technologies, reduced immune responses and scalable manufacturing as key trends, with North America dominating in 2025 and Asia-Pacific expected to grow rapidly.

ResearchAndMarkets.com added a report on the next-generation AAV gene therapy delivery market, covering engineered capsids, targeting, safety and scalable manufacturing.

The report points to engineered capsid technologies, reduced immune responses and scalable manufacturing as key trends, with North America dominating in 2025 and Asia-Pacific expected to grow rapidly.